Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the NF1 Gene in the Osseous Lesion

REINHARD E. FRIEDRICH, ANDREAS M. LUEBKE, ULRICH SCHÜLLER, CHRISTIAN HAGEL, FELIX K. KOHLRUSCH, ILSE WIELAND and MARTIN ZENKER
Anticancer Research June 2022, 42 (6) 2945-2952; DOI: https://doi.org/10.21873/anticanres.15777
REINHARD E. FRIEDRICH
1Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rfriedrich@uke.de
ANDREAS M. LUEBKE
2Institute of Pathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULRICH SCHÜLLER
3Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
4Department of Pediatric Hematology and Oncology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
5Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIAN HAGEL
3Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FELIX K. KOHLRUSCH
1Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ILSE WIELAND
6Institute of Human Genetics, Otto-von-Guericke University, Magdeburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARTIN ZENKER
6Institute of Human Genetics, Otto-von-Guericke University, Magdeburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: In the autosomal dominant hereditary disease neurofibromatosis type 1 (NF1), lesions of the jaw develop in isolated cases, which are diagnosed as central giant cell granuloma (CGCG). This study aimed to clarify the genetic basis of a bone lesion in a syndromic patient. Case Report: The NF1 patient had developed a CGCG that recurred after local excision. Blood and tumor tissue were studied for NF1 mutations using advanced molecular genetic methods. Examinations of blood and tumor tissue provided evidence of the constitutive mutation in both samples. A further mutation was detected in the tumor, which was interpreted as a somatic mutation. The detection of somatic mutation in the tissue was successful both on native and routinely fixed material. Conclusion: The study supports current assessments of CGCG as a benign neoplasm. In NF1 patients, the phenotype seems to imply bi-allelic loss of the NF1 gene. The detection of both mutations in routinely fixed tissue allows studies of archived tissue samples with this diagnosis.

Key Words:
  • Neurofibromatosis type 1
  • plexiform neurofibroma
  • central giant cell granuloma
  • RASopathy
  • root resorption

Neurofibromatosis type 1 (NF1, MIM 162200) is an autosomal dominant inherited disease that causes a plethora of signs and symptoms. A regularly detected feature of the disease is a neoplasm arising from the cells that constitute the sheaths of peripheral nerves, the Schwann cells (1). The most prominent neoplasm arising in NF1 (2, 3), termed neurofibroma (1), mostly consists of tumor cells with Schwann cell differentiation. Neurofibromas are frequent cutaneous tumors in NF1 patients. However, tumors also develop in internal organs. Intraosseous neurofibroma is a well-known entity, which is also proven in the facial skeleton, particularly in the mandible (4, 5). However, NF1-associated intraosseous neurofibroma of the mandible is rare (6) and intraosseous lesions of the jaws are often not clearly diagnosed on radiological examination. In NF1 patients, in addition to the rare intraosseous nerve sheath tumors, other non-odontogenic (6) and odontogenic (7, 8) lesions must be considered as causes of osteolysis. A rare osseous lesion is the so-called central giant cell granuloma (CGCG), also called central giant cell lesion (9). Relatively rarely reported is the CGCG of the jaw in NF1 (10-19). Individual reports have reported germline and somatic mutations of the NF1 gene in NF1-associated CGCG (15) and specifically in tumor cells of the lesions (18, 19). This report adds a further NF1-associated CGCG case and provides evidence of mutations in NF1 in both alleles.

Case Report

The female patient, aged 22 years, presented at the Clinic of Oral and Craniomaxillofacial Surgery, University Hospital Hamburg-Eppendorf, for the treatment of an extensive plexiform neurofibroma of the thoraco-abdominal region. The patient had numerous café-au-lait spots and axillary freckling of the integument. During routine diagnostics, an orthopantomographic view of the jaws (OPT) was taken (Figure 1A). On the radiograph, a sharply delineated radio-translucent lesion in the region of the right mandibular angle was detected, which had developed in topographical proximity to the molars. A multi-lobulated cyst of the jaw was suspected. Oral inspection revealed an intact, rosy mucosa with no apparent osseous pathology. The teeth of the 4th quadrant were firm, showed no bleeding after probing the periodontium, and responded adequately to cold stimuli, except for the third molar.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Radiological representation (orthopantomography) of the bone lesion of the right angle of the jaw in a patient with neurofibromatosis type 1 (cropped images). A) Initial findings show multiple lobulated bone destruction extending both into the mandibular ramus and anteriorly to the apex of the adjacent molar. Bone destruction extends caudally to the mandibular canal. B) Findings after removal of the lesion and extraction of the molar. C) Approximately six months after removal of the giant cell lesion, the defect in the ramus has re-ossified. In contrast, a sharply demarcated, residual osteolytic lesion demarcates around the root of the second molar. D) This finding increases somewhat in the following 15 months (findings prior to excision of the recurrent tumor).

Due to the urgent treatment need of the very painful thoraco-abdominal tumor, the clarification of the oral findings was postponed. Six months after the first extensive tumor reduction of the trunk, the patient came for a follow-up examination. The OPT showed the known osteolytic findings unchanged. Under general anesthesia, the right side of the mandible was exposed through an angled muco-periosteal incision, and the cortical bone was trephined over the lesion. Underneath, a cavity filled with solid, gelatinous soft tissue of greyish color was exposed and the tumor tissue was excised. The roots of the third molar were not covered by bone, in direct contact with the soft tissue tumor, and had to be extracted. The uppermost layer of the bone bordering the lesion was removed with the drill, carefully sparing the exposed alveolar nerve (Figure 1B). The defect was filled with collagen and the wound was closed. The course of wound healing was uncomplicated.

Six months after the first intervention for the jaw lesion, the patient came back for a check-up of the trunk and jaw findings (Figure 1C). The osteolysis around the ramus and the third molar was re-ossified. However, well-demarcated radiolucency remained in the periapical area of the second molar, which was interpreted as a recurrence of the lesion. The patient did not appear until 15 months later for a re-investigation of the jaw findings. OPT of the jaws revealed some increase in size of the known mandibular periapical lesion (Figure 1D and Figure 2). Assuming a local recurrence, the situs was exposed in a procedure identical to the first intervention. A soft tissue lesion was present in the bone cavity, which was identical in texture and visual appearance to the primary findings. A second excision of the lesion was performed. The patient did not wish to have the molar extracted, which reached into the cavity with its roots and was in direct contact with the lesion. The healing process again was unremarkable. The serological findings showed no pathological parameters of the calcium metabolism during the entire treatment. The patient has consented in writing to the genetic examination of the samples and the publication of the examination and treatment results.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Recurrence of a giant cell lesion of the lower jaw in neurofibromatosis type 1 in cone beam computed tomography (cropped images, right side of bone depicted). A) Osteolysis of the mandible with thinning of the vestibular cortical bones. B) Root apex of the second molar in the lesion (A and B: axial section). C) Multiple lobulated intraosseous lesion (coronal section). D) The lobulated lesion extends caudally to the nerve canal (sagittal section).

Histology. The bone biopsy of the right second mandibular molar revealed bone tissue with a lesion composed of spindle-shaped and polygonal cells with scattered osteoclast-type multinucleated giant cells, hemorrhage, and hemosiderin pigment (Figure 3A and B). The lesion was unencapsulated and infiltrated the adjacent bone that showed reactive changes (Figure 3C). Additionally, resorption of the dental roots was observed (Figure 3D and E). The findings were characteristic of CGCG. The second excision revealed a relapse of the same lesion (Figure 3F).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Histology of giant cell granuloma in neurofibromatosis type 1. A) Spindle-shaped and polygonal cells with scattered osteoclast-type multinucleated giant cells [hematoxylin-eosin (HE) stain]. B) Higher magnification points out hemorrhage and hemosiderin pigment (HE stain). C) Infiltration of adjacent bone (HE stain). D) Resorption of dentin [undecalcified methylmethacrylate embedding (MMA), toluidine-blue stain]. E) Higher magnification of resorption site (MMA, toluidine-blue stain). F) Identical finding [central giant cell granuloma (CGCG)] in the second excision (HE stain). Scale bar: 200 μm.

Peripheral nerve sheath tumors. Resection of the tumor from the trunk revealed nodular-plexiform neurofibroma. Further cutaneous neurofibromas were excised from the trunk and extremities (Figure 4).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Histology of neurofibroma in neurofibromatosis type 1 patient with central giant cell granuloma of the jaw. A) Cutaneous neurofibroma consisting of spindle shaped cells with intermingling collagen fibers. B) Diffuse plexiform neurofibroma with intraneural tumor portions with focal loose texture (left margin) and diffuse tumor growth between the encapsulated tumor areas (upper and lower right corner). Scale bar: 500 μm.

Molecular genetics. Blood and native GCGG tissue as well as fixed tumor material from the bone lesion were examined for mutations in the NF1 gene.

Fresh tumor sample analysis. For mutation analysis of native tissue DNA, the coding sequences and flanking intronic regions of the NF1 gene (MIM 613113, ENST00000356175, exons 1-58) were enriched using a Nextera DNA Flex custom enrichment kit (Illumina, San Diego, CA, USA) and sequencing was carried out on the next-generation sequencing platform MiSeq (Illumina). The analysis of the sequence data was carried out with the help of the SeqNext module of the SEQUENCE Pilot software (JSI Medical Systems, Ettenheim, Germany). Variants with probable pathogenic importance within the sequence of the examined gene were independently validated by bidirectional Sanger sequencing on an ABI 3500 L sequencer (Thermo-Fisher, Waltham, MA, USA) after PCR amplification from the patient’s DNA and purification of the PCR fragments. The bioinformatic deletion and duplication analysis was performed with varfeed 1.9.0 (Limbus Medical Technologies GmbH, Rostock, Germany). Analysis of the CGCG showed the pathogenic NF1 mutation c.3942G>A (p.Trp1314*) in a heterozygous state. Furthermore, another pathogenic sequence change c.289C>T (p.Gln97*) of the NF1 gene was detected in the tumor tissue DNA in a mosaic state with a variant allele frequency of 7.2%.

Analysis of formalin-fixed, paraffin-embedded tumor tissue. Independently from native tissue analysis, DNA extraction from the formalin-fixed and paraffin-embedded tumor material of the mandible was investigated for NF1 mutations. Mutation analysis was done after next-generation sequencing (QIASeq Targeted DNA Panel CDHS-21330Z-424, Qiagen, Hilden, Germany). Analysis was performed with CLC Genomics Workbench 21 using the GRCh37 reference genome. The data set was filtered for non-synonymous exonic single nucleotide variants (SNVs) with an allele frequency of >5%, which are stored in the 1,000-genome database as unknown polymorphisms. The following mutations were detected in the CGCG: 1. The NF1 gene variant c.3942G>A, (p.Trp1314*), variant allele frequency 52%, coverage 3451. 2. The NF1 gene variant c.289C>T, (p.Gln97*), variant allele frequency 11%, coverage 3584. Both mutations were considered relevant for tumor development.

The heterozygous mutation c.3942G>A (p.Trp1314*) has been repeatedly recorded as pathogenic in the databases LOVD (ID NF1_000419) and ClinVar (ID 849712). It is very likely the underlying germline NF1 mutation in the patient. Also, the mutation has been described several times in the literature (20-23). In addition to the germline mutation, the mosaic nonsense mutation c.289C>T (p.Gln97*) was detected in tumor tissue. This alteration is interpreted as a second hit on the homologous allele of the CGCG tumor cells. The mutation is listed as pathogenic in ClinVar database (ID 818189) and is also described in the literature (23). Both variants are considered as causing loss of function alleles. The genetic tests therefore support the assumption that the CGCG of the mandible was a manifestation of NF1 and was driven by bi-allelic NF1 defects in the tumor cells.

Discussion

So far, somatic mutations of the NF1 gene in NF1-associated CGCG of the jaws have been demonstrated in native material of lesions and in cell culture (15, 18, 19). Elaborate conditioning and enrichment of the tumor cells of the CGCG in cell culture were necessary to isolate the tumor cells and detect the tumor specific NF1 mutations (18, 19). We report here identical germline and somatic mutations in an NF1-associated recurrent CGCG after independent analysis of native and fixed specimens, which have been prepared from the same lesion. Current technical standards offer reliable analysis of archival material on this rare bone disease.

The radiological visualization of osteolysis of the jaws requires the differential diagnosis of numerous diseases, including cancer. NF1 is an autosomal dominant hereditary disease characterized primarily by tumors of the peripheral nervous system. Further tumors occur in the setting of NF1, which identify this disease as a multi-systemic tumor predisposition syndrome (24). Indeed, NF1 is a relatively common genetic disorder that predisposes affected patients to cancer (25).

It is assumed that the tumors in NF1 originate primarily from derivatives of the neural crest (26, 27). Both Schwann cells and most of the skull bones are derivatives of the neural crest (28-30). Therefore, an association of certain neoplastic jaw lesions such as CGCG with the disease is presumptive for NF1 patients. Indeed, a connection between the CGCG and NF1 has been suspected earlier (18). However, while the CGCG tumor cell has been partially characterized, its origin is unknown. Until a few years ago, the causal (genetic) origin of CGCG was largely unknown. CGCG develops in NF1 and other syndromes, the common feature of which are causative mutations that affect the rat sarcoma homologue in human (RAS) pathway (24, 30). The syndromes caused by mutations in genes encoding components or modulators of the RAS pathway have been grouped together as RASopathies. The phenotypes of different RASopathies show significant overlaps. The overlaps of clinical findings make comprehensible that individual findings, for example CGCG of the jaw, cannot be reliably assigned to a distinct syndrome based on the histological diagnosis alone (30-33). Furthermore, the lesion is a sporadic finding well known in oral medicine (9). Recent studies revealed that somatic mutations in RAS pathway genes are the cause of sporadic non-syndromic CGCG cases (9). Evidence of RAS pathway mutations in CGCG provide arguments for defining CGCG as a neoplasm. However, in both sporadic and many syndrome-associated CGCG, the lesions already developed with evidence of constitutive RAS-mutations (9). In contrast, according to the few cases published on the subject in NF1, bi-allelic loss of NF1 gene is necessary for the development of CGCG in this tumor predisposition syndrome (18, 19). CGCG of jaws in NF1 without evidence of the second hit can probably be attributed to methodological limitations (34, 35) or a pathogenesis of the lesion (cherubism-like tumorous expansion of facial bones) independent of somatic NF1 mutations (35).

Conclusion

In NF1 patients, CGCG of the jaw is a neoplasm associated with somatic second-hit NF1 mutations in the tumor cells. After excision, the lesion has a tendency to local recurrence. Long-term control of the region after removal of the lesion is advisable.

Footnotes

  • Authors’ Contributions

    Treatment of patient, conceptualization of the study: REF; genetic examinations: MZ, IW, US; histological examinations: CH, AML; literature research and evaluation, drafting of the manuscript: REF, FKK; final approval of manuscript: All Authors.

  • Conflicts of Interest

    The Authors declare that there are no conflicts of interest regarding this publication.

  • Received March 21, 2022.
  • Revision received April 14, 2022.
  • Accepted April 15, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Von Recklinghausen FD
    : Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin, Hirschwald, 1882.
  2. ↵
    1. Kluwe L ,
    2. Friedrich R and
    3. Mautner VF
    : Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24(3): 283-285, 1999. PMID: 10451710. DOI: 10.1002/(sici)1098-2264(199903)24:3<283::aid-gcc15>3.0.co;2-k
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kluwe L ,
    2. Friedrich RE and
    3. Mautner VF
    : Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet 113(1): 65-69, 1999. PMID: 10459349. DOI: 10.1016/s0165-4608(99)00006-0
    OpenUrlCrossRefPubMed
  4. ↵
    1. Blackwood HJ and
    2. Lucas RB
    : Neurofibroma of the mandible. Proc R Soc Med 44(10): 864-865, 1951. PMID: 14891790.
    OpenUrlPubMed
  5. ↵
    1. Prescott GH and
    2. White RE
    : Solitary, central neurofibroma of the mandible: report of case and review of the literature. J Oral Surg 28(4): 305-309, 1970. PMID: 4907056.
    OpenUrlPubMed
  6. ↵
    1. Friedrich RE and
    2. Scheuer HT
    : Non-odontogenic intraosseous radiolucent lesions of the mandibular body are rare findings on panoramic views of patients with neurofibromatosis type 1. Anticancer Res 39(4): 1971-1985, 2019. PMID: 30952741. DOI: 10.21873/anticanres.13308
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Visnapuu V ,
    2. Pienihäkkinen K ,
    3. Peltonen S ,
    4. Happonen RP and
    5. Peltonen J
    : Neurofibromatosis 1 and dental caries. Clin Oral Investig 15(1): 119-121, 2011. PMID: 19727860. DOI: 10.1007/s00784-009-0341-x
    OpenUrlCrossRefPubMed
  8. ↵
    1. Friedrich RE and
    2. Reul A
    : Decayed, missing, and restored teeth in patients with Neurofibromatosis Type 1. J Clin Exp Dent 10(2): e107-e115, 2018. PMID: 29670726. DOI: 10.4317/jced.54561
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gomes CC ,
    2. Diniz MG ,
    3. Bastos VC ,
    4. Bernardes VF and
    5. Gomez RS
    : Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next-generation sequencing. J Pathol 250(2): 126-133, 2020. PMID: 31705763. DOI: 10.1002/path.5365
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kerl H and
    2. Schroll K
    : [Multiple giant-cell granuloma of the jaw associated with Recklinghausen’s neurofibromatosis]. Wien Klin Wochenschr 83(52): 938-941, 1971. PMID: 5002595.
    OpenUrlPubMed
    1. Ruggieri M ,
    2. Pavone V ,
    3. Polizzi A ,
    4. Albanese S ,
    5. Magro G ,
    6. Merino M and
    7. Duray PH
    : Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87(1): 67-72, 1999. PMID: 9927083. DOI: 10.1016/s1079-2104(99)70297-0
    OpenUrlCrossRefPubMed
    1. Ardekian L ,
    2. Manor R ,
    3. Peled M and
    4. Laufer D
    : Bilateral central giant cell granulomas in a patient with neurofibromatosis: report of a case and review of the literature. J Oral Maxillofac Surg 57(7): 869-872, 1999. PMID: 10416639. DOI: 10.1016/s0278-2391(99)90833-9
    OpenUrlCrossRefPubMed
    1. Edwards PC ,
    2. Fantasia JE ,
    3. Saini T ,
    4. Rosenberg TJ ,
    5. Sachs SA and
    6. Ruggiero S
    : Clinically aggressive central giant cell granulomas in two patients with neurofibromatosis 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102(6): 765-772, 2006. PMID: 17138179. DOI: 10.1016/j.tripleo.2005.10.038
    OpenUrlCrossRefPubMed
    1. van Capelle CI ,
    2. Hogeman PH ,
    3. van der Sijs-Bos CJ ,
    4. Heggelman BG ,
    5. Idowu B ,
    6. Slootweg PJ ,
    7. Wittkampf AR and
    8. Flanagan AM
    : Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr 166(9): 905-909, 2007. PMID: 17120035. DOI: 10.1007/s00431-006-0334-6
    OpenUrlCrossRefPubMed
  11. ↵
    1. Friedrich RE ,
    2. Mautner VF and
    3. Scheuer HA
    : Loss of heterozygosity in tumor cells of a recurrent mandibular giant cell granuloma in neurofibromatosis type 1. Anticancer Res 27(4A): 2079-2083, 2007. PMID: 17649825.
    OpenUrlAbstract/FREE Full Text
    1. Chrcanovic BR ,
    2. Gomez RS and
    3. Freire-Maia B
    : Neurofibromatosis type 1 associated with bilateral central giant cell granuloma of the mandible. J Craniomaxillofac Surg 39(7): 538-543, 2011. PMID: 21071237. DOI: 10.1016/j.jcms.2010.10.014
    OpenUrlCrossRefPubMed
    1. Jyothi SK ,
    2. Pushpanjali M ,
    3. Chandrasekhar R and
    4. Devarampatti N
    : Central giant cell granuloma in a patient with neurofibromatosis type 1: a case report. International Journal of Oral-Medical Sciences 11(3): 223-228, 2021. DOI: 10.5466/IJOMS.11.223
    OpenUrlCrossRef
  12. ↵
    1. Stewart DR ,
    2. Brems H ,
    3. Gomes AG ,
    4. Ruppert SL ,
    5. Callens T ,
    6. Williams J ,
    7. Claes K ,
    8. Bober MB ,
    9. Hachen R ,
    10. Kaban LB ,
    11. Li H ,
    12. Lin A ,
    13. McDonald M ,
    14. Melancon S ,
    15. Ortenberg J ,
    16. Radtke HB ,
    17. Samson I ,
    18. Saul RA ,
    19. Shen J ,
    20. Siqveland E ,
    21. Toler TL ,
    22. van Maarle M ,
    23. Wallace M ,
    24. Williams M ,
    25. Legius E and
    26. Messiaen L
    : Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genet Med 16(6): 448-459, 2014. PMID: 24232412. DOI: 10.1038/gim.2013.163
    OpenUrlCrossRefPubMed
  13. ↵
    1. Friedrich RE ,
    2. Grob TJ ,
    3. Hollants S ,
    4. Zustin J ,
    5. Spaepen M ,
    6. Mautner VF ,
    7. Luebke AM ,
    8. Hagel C ,
    9. Legius E and
    10. Brems H
    : Recurrent multilocular mandibular giant cell granuloma in neurofibromatosis type 1: Evidence for second hit mutation of NF1 gene in the jaw lesion and treatment with curettage and bone substitute materials. J Craniomaxillofac Surg 44(8): 1054-1060, 2016. PMID: 27316856. DOI: 10.1016/j.jcms.2016.05.010
    OpenUrlCrossRefPubMed
  14. ↵
    1. Upadhyaya M ,
    2. Osborn MJ ,
    3. Maynard J ,
    4. Kim MR ,
    5. Tamanoi F and
    6. Cooper DN
    : Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 99(1): 88-92, 1997. PMID: 9003501. DOI: 10.1007/s004390050317
    OpenUrlCrossRefPubMed
    1. Toliat MR ,
    2. Erdogan F ,
    3. Gewies A ,
    4. Fahsold R ,
    5. Buske A ,
    6. Tinschert S and
    7. Nürnberg P
    : Analysis of the NF1 gene by temperature gradient gel electrophoresis reveals a high incidence of mutations in exon 4b. Electrophoresis 21(3): 541-544, 2000. PMID: 10726756. DOI: 10.1002/(SICI)1522-2683(20000201)21:3<541::AID-ELPS541>3.0.CO;2-L
    OpenUrlCrossRefPubMed
    1. Sabbagh A ,
    2. Pasmant E ,
    3. Imbard A ,
    4. Luscan A ,
    5. Soares M ,
    6. Blanché H ,
    7. Laurendeau I ,
    8. Ferkal S ,
    9. Vidaud M ,
    10. Pinson S ,
    11. Bellanné-Chantelot C ,
    12. Vidaud D ,
    13. Parfait B and
    14. Wolkenstein P
    : NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat 34(11): 1510-1518, 2013. PMID: 23913538. DOI: 10.1002/humu.22392
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zhu G ,
    2. Zheng Y ,
    3. Liu Y ,
    4. Yan A ,
    5. Hu Z ,
    6. Yang Y ,
    7. Xiang S ,
    8. Li L ,
    9. Chen W ,
    10. Peng Y ,
    11. Zhong N and
    12. Mei H
    : Identification and characterization of NF1 and non-NF1 congenital pseudarthrosis of the tibia based on germline NF1 variants: genetic and clinical analysis of 75 patients. Orphanet J Rare Dis 14(1): 221, 2019. PMID: 31533797. DOI: 10.1186/s13023-019-1196-0
    OpenUrlCrossRefPubMed
  16. ↵
    1. Legius E ,
    2. Marchuk DA ,
    3. Collins FS and
    4. Glover TW
    : Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3(2): 122-126, 1993. PMID: 8499945. DOI: 10.1038/ng0293-122
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rauen KA ,
    2. Huson SM ,
    3. Burkitt-Wright E ,
    4. Evans DG ,
    5. Farschtschi S ,
    6. Ferner RE ,
    7. Gutmann DH ,
    8. Hanemann CO ,
    9. Kerr B ,
    10. Legius E ,
    11. Parada LF ,
    12. Patton M ,
    13. Peltonen J ,
    14. Ratner N ,
    15. Riccardi VM ,
    16. van der Vaart T ,
    17. Vikkula M ,
    18. Viskochil DH ,
    19. Zenker M and
    20. Upadhyaya M
    : Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet A 167A(1): 1-10, 2015. PMID: 25393061. DOI: 10.1002/ajmg.a.36793
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wallace MR ,
    2. Marchuk DA ,
    3. Andersen LB ,
    4. Letcher R ,
    5. Odeh HM ,
    6. Saulino AM ,
    7. Fountain JW ,
    8. Brereton A ,
    9. Nicholson J and
    10. Mitchell AL
    : Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249(4965): 181-186, 1990. PMID: 2134734. DOI: 10.1126/science.2134734
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Bolande RP
    : Neurofibromatosis – the quintessential neurocristopathy: pathogenetic concepts and relationships. Adv Neurol 29: 67-75, 1981. PMID: 6798844.
    OpenUrlPubMed
  20. ↵
    1. Trainor PA ,
    2. Melton KR and
    3. Manzanares M
    : Origins and plasticity of neural crest cells and their roles in jaw and craniofacial evolution. Int J Dev Biol 47(7-8): 541-553, 2003. PMID: 14756330.
    OpenUrlPubMed
    1. Jessen KR and
    2. Mirsky R
    : The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci 6(9): 671-682, 2005. PMID: 16136171. DOI: 10.1038/nrn1746
    OpenUrlCrossRefPubMed
  21. ↵
    1. Martik ML and
    2. Bronner ME
    : Riding the crest to get a head: neural crest evolution in vertebrates. Nat Rev Neurosci 22(10): 616-626, 2021. PMID: 34471282. DOI: 10.1038/s41583-021-00503-2
    OpenUrlCrossRefPubMed
    1. Sinnott BP and
    2. Patel M
    : Giant cell lesion of the jaw as a presenting feature of Noonan syndrome. BMJ Case Rep 2018: bcr2017224115, 2018. PMID: 29848529. DOI: 10.1136/bcr-2017-224115
    OpenUrlCrossRefPubMed
    1. Zenker M
    : Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr Opin Pediatr 23(4): 443-451, 2011. PMID: 21750428. DOI: 10.1097/MOP.0b013e32834881dd
    OpenUrlCrossRefPubMed
  22. ↵
    1. Yazdizadeh M ,
    2. Tapia JL ,
    3. Baharvand M and
    4. Radfar L
    : A case of neurofibromatosis-Noonan syndrome with a central giant cell granuloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98(3): 316-320, 2004. PMID: 15356469. DOI: 10.1016/S1079210404000654
    OpenUrlCrossRefPubMed
  23. ↵
    1. Krammer U ,
    2. Wimmer K ,
    3. Wiesbauer P ,
    4. Rasse M ,
    5. Lang S ,
    6. Müllner-Eidenböck A and
    7. Frisch H
    : Neurofibromatosis 1: a novel NF1 mutation in an 11-year-old girl with a giant cell granuloma. J Child Neurol 18(5): 371-373, 2003. PMID: 12822827. DOI: 10.1177/08830738030180051901
    OpenUrlCrossRefPubMed
  24. ↵
    1. Friedrich RE ,
    2. Zustin J ,
    3. Luebke AM ,
    4. Rosenbaum T ,
    5. Gosau M ,
    6. Hagel C ,
    7. Kohlrusch FK ,
    8. Wieland I and
    9. Zenker M
    : Neurofibromatosis type 1 with cherubism-like phenotype, multiple osteolytic bone lesions of lower extremities, and Alagille-syndrome: case report with literature survey. In Vivo 35(3): 1711-1736, 2021. PMID: 33910856. DOI: 10.21873/invivo.12431
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (6)
Anticancer Research
Vol. 42, Issue 6
June 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the NF1 Gene in the Osseous Lesion
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the NF1 Gene in the Osseous Lesion
REINHARD E. FRIEDRICH, ANDREAS M. LUEBKE, ULRICH SCHÜLLER, CHRISTIAN HAGEL, FELIX K. KOHLRUSCH, ILSE WIELAND, MARTIN ZENKER
Anticancer Research Jun 2022, 42 (6) 2945-2952; DOI: 10.21873/anticanres.15777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the NF1 Gene in the Osseous Lesion
REINHARD E. FRIEDRICH, ANDREAS M. LUEBKE, ULRICH SCHÜLLER, CHRISTIAN HAGEL, FELIX K. KOHLRUSCH, ILSE WIELAND, MARTIN ZENKER
Anticancer Research Jun 2022, 42 (6) 2945-2952; DOI: 10.21873/anticanres.15777
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes
  • The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma
  • Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Neurofibromatosis type 1
  • plexiform neurofibroma
  • central giant cell granuloma
  • RASopathy
  • root resorption
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire